Kowa and Lilly launch pitavastatin in the US
This article was originally published in Scrip
Executive Summary
Kowa Pharmaceuticals America (KPA) and co-promotion partner Lilly have launched Kowa's cholesterol-lowering product Livalo (pitavastatin) in the US, as an adjunctive therapy to diet for the treatment of adult primary hyperlipidaemia and mixed dyslipidaemia.